CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Recurrent Ovarian Epithelial Cancer
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent Ovarian Epithelial Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ziv-Aflibercept National Cancer Institute (NCI) | Phase 2 | BB |
Ixabepilone Yale University | Phase 2 | BB |
Temsirolimus University of Southern California | Phase 2 | BB |
TRASTUZUMAB OHSU Knight Cancer Institute | Phase 2 | BB |
Sargramostim Barbara Ann Karmanos Cancer Institute | Phase 2 | BB |
View all 39 →
Same molecule, other indications
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →